Valerio Therapeutics Société anonyme (ALVIO.PA)
EUR 0.08
(3.31%)
EUR 0.08
(3.31%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 6.9 Million EUR | -21.07% |
| 2022 | 8.75 Million EUR | -22.84% |
| 2021 | 11.34 Million EUR | 165.08% |
| 2020 | 4.27 Million EUR | -42.28% |
| 2019 | 7.41 Million EUR | 12.42% |
| 2018 | 6.59 Million EUR | 1098.73% |
| 2017 | 550 Thousand EUR | -13.66% |
| 2016 | 637 Thousand EUR | -11.4% |
| 2015 | 719 Thousand EUR | 29.51% |
| 2014 | 555.17 Thousand EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| 2011 | - EUR | 0.0% |
| 2010 | - EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | -100.0% |
| 2005 | 700.55 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 11.42 Million EUR | 65.49% |
| 2024 Q2 | 11.42 Million EUR | 0.0% |
| 2023 Q4 | 6.9 Million EUR | -4.34% |
| 2023 Q3 | 7.21 Million EUR | -9.73% |
| 2023 FY | 6.9 Million EUR | -21.07% |
| 2023 Q2 | 7.99 Million EUR | 0.0% |
| 2023 Q1 | 7.99 Million EUR | -8.61% |
| 2022 Q1 | 9.93 Million EUR | -12.39% |
| 2022 FY | 8.75 Million EUR | -22.84% |
| 2022 Q4 | 8.75 Million EUR | 0.0% |
| 2022 Q3 | 8.75 Million EUR | -37.76% |
| 2022 Q2 | 14.05 Million EUR | 41.5% |
| 2021 FY | 11.34 Million EUR | 165.08% |
| 2021 Q1 | 6.72 Million EUR | 57.25% |
| 2021 Q3 | 6.51 Million EUR | -3.23% |
| 2021 Q4 | 11.34 Million EUR | 74.19% |
| 2021 Q2 | 6.72 Million EUR | 0.0% |
| 2020 Q3 | 4.27 Million EUR | -34.51% |
| 2020 Q2 | 6.53 Million EUR | 0.0% |
| 2020 Q4 | 4.27 Million EUR | 0.0% |
| 2020 FY | 4.27 Million EUR | -42.28% |
| 2020 Q1 | 6.53 Million EUR | -11.87% |
| 2019 Q1 | 8.87 Million EUR | 34.57% |
| 2019 FY | 7.41 Million EUR | 12.42% |
| 2019 Q4 | 7.41 Million EUR | 0.0% |
| 2019 Q3 | 7.41 Million EUR | -16.46% |
| 2019 Q2 | 8.87 Million EUR | 0.0% |
| 2018 Q1 | - EUR | -100.0% |
| 2018 Q2 | 7.06 Million EUR | 0.0% |
| 2018 Q3 | 6.59 Million EUR | -6.71% |
| 2018 Q4 | 6.59 Million EUR | 0.0% |
| 2018 FY | 6.59 Million EUR | 1098.73% |
| 2017 Q1 | - EUR | -100.0% |
| 2017 FY | 550 Thousand EUR | -13.66% |
| 2017 Q4 | 550 Thousand EUR | 0.0% |
| 2017 Q3 | - EUR | -100.0% |
| 2017 Q2 | 4.71 Million EUR | 0.0% |
| 2016 FY | 637 Thousand EUR | -11.4% |
| 2016 Q3 | - EUR | -100.0% |
| 2016 Q2 | 702 Thousand EUR | 0.0% |
| 2016 Q1 | - EUR | -100.0% |
| 2016 Q4 | 637 Thousand EUR | 0.0% |
| 2015 Q2 | 668.07 Thousand EUR | 0.0% |
| 2015 Q4 | 719 Thousand EUR | 0.0% |
| 2015 FY | 719 Thousand EUR | 29.51% |
| 2015 Q1 | - EUR | -100.0% |
| 2015 Q3 | - EUR | -100.0% |
| 2014 Q3 | - EUR | 0.0% |
| 2014 Q4 | 555.17 Thousand EUR | 0.0% |
| 2014 Q2 | - EUR | 0.0% |
| 2014 FY | 555.17 Thousand EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2013 Q4 | - EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| 2013 Q3 | - EUR | 0.0% |
| 2013 Q2 | - EUR | 0.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 Q4 | - EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2011 Q2 | 2.18 Million EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 Q2 | 1.06 Million EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | -100.0% |
| 2005 FY | 700.55 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -527.248% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 84.549% |
| Adocia SA | 4.54 Million EUR | -52.115% |
| Aelis Farma SA | 2.04 Million EUR | -237.207% |
| Biophytis S.A. | 3.11 Million EUR | -121.986% |
| Advicenne S.A. | 15.89 Million EUR | 56.555% |
| genOway Société anonyme | 5.51 Million EUR | -25.125% |
| IntegraGen SA | 642.28 Thousand EUR | -975.232% |
| Medesis Pharma S.A. | 1.2 Million EUR | -475.5% |
| Neovacs S.A. | 650 Thousand EUR | -962.462% |
| NFL Biosciences SA | 39.2 Thousand EUR | -17515.999% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -58.521% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -252.288% |
| Sensorion SA | 1.24 Million EUR | -456.527% |
| Theranexus Société Anonyme | 2.46 Million EUR | -180.65% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -77.168% |
| TheraVet SA | 1 Million EUR | -590.187% |
| argenx SE | 15.35 Million EUR | 55.021% |
| BioSenic S.A. | 15.57 Million EUR | 55.654% |
| Celyad Oncology SA | 902 Thousand EUR | -665.632% |
| DBV Technologies S.A. | 4.52 Million USD | -52.585% |
| Galapagos NV | 4.94 Million EUR | -39.684% |
| Genfit S.A. | 62.25 Million EUR | 88.907% |
| GeNeuro SA | 6.49 Million EUR | -6.372% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -1907.558% |
| Innate Pharma S.A. | 30.6 Million EUR | 77.437% |
| Inventiva S.A. | 25.61 Million EUR | 73.04% |
| MaaT Pharma SA | 5.42 Million EUR | -27.3% |
| MedinCell S.A. | 52.8 Million EUR | 86.92% |
| Nanobiotix S.A. | 41.66 Million EUR | 83.423% |
| Onward Medical N.V. | 16.3 Million EUR | 57.647% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -100.138% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 80.551% |
| Oxurion NV | 117 Thousand EUR | -5802.564% |
| Pharming Group N.V. | 123.65 Million EUR | 94.415% |
| Poxel S.A. | 40.14 Million EUR | 82.797% |
| GenSight Biologics S.A. | 1.04 Million EUR | -558.969% |
| Transgene SA | 17 Thousand EUR | -40523.529% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.76% |
| Valneva SE | 132.76 Million EUR | 94.798% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |